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Abstract
Background Serelaxin showed beneficial effects on clin-
ical outcome and trajectories of renal markers in patients
with acute heart failure. We aimed to study the interaction
between renal function and the treatment effect of
serelaxin.
Methods In the current post hoc analysis of the RELAX-
AHF trial, we included all patients with available estimated
glomerular filtration rate (eGFR) at baseline (n = 1132).
Renal impairment was defined as an eGFR\60 ml/min/
1.73 m2 estimated by creatinine.
Results 817 (72.2 %) patients had a baseline
eGFR\60 ml/min/1.73 m2. In placebo-treated patients,
baseline renal impairment was related to a higher 180 day
cardiovascular (HR 3.12, 95 % CI 1.33–7.30) and all-cause
mortality (HR 2.81, 95 % CI 1.34–5.89). However, in
serelaxin-treated patients, the risk of cardiovascular and
all-cause mortality was less pronounced (HR 1.19, 95 % CI
0.54 –2.64; p for interaction = 0.106, and HR 1.15 95 %
CI 0.56–2.34 respectively; p for interaction = 0.088). In
patients with renal impairment, treatment with serelaxin
resulted in a more pronounced all-cause mortality reduc-
tion (HR 0.53, 95 % CI 0.34–0.83), compared with patients
without renal impairment (HR 1.30, 95 % CI 0.51–3.29).
Conclusion Renal dysfunction was associated with higher
cardiovascular and all-cause mortality in placebo-treated
patients, but not in serelaxin-treated patients. The observed
reduction in (cardiovascular) mortality in RELAX-AHF
was more pronounced in patients with renal dysfunction.
These observations need to be confirmed in the ongoing
RELAX-AHF-2 trial.
Keywords Serelaxin  Acute heart failure  Renal
function  Renal impairment  Number needed to treat
Introduction
Renal dysfunction and worsening of renal function are
frequently found in acute heart failure patients and are both
associated with prolonged hospital stay, and higher risk of
rehospitalization and mortality [1–7]. The Relaxin in Acute
Heart Failure (RELAX-AHF) trial studied the effects of
serelaxin, a novel recombinant of the naturally occurring
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human relaxin-2 vasoactive peptide, intravenously admin-
istrated for 48 h in acute heart failure patients [8]. The
RELAX-AHF demonstrated that treatment with serelaxin
resulted in beneficial effects on dyspnea, compared with
placebo. Interestingly, while only administrated for 48 h,
serelaxin resulted in a significant reduction of cardiovas-
cular (CV) and all-cause death up to 180 days [8]. A post
hoc analysis demonstrated that patients treated with sere-
laxin had lower increases of markers of end-organ damage,
including the renal markers creatinine and cystatin C,
during hospitalization [9]. These observations suggested
that serelaxin may have beneficial effects on renal function
in patients with acute heart failure. In fact, in studies
investigating the (renal) hemodynamic effects of serelaxin
in healthy volunteers, chronic heart failure, and acute heart
failure, and a study investigating the antifibrotic effects of
serelaxin in patients with diffuse scleroderma both found
that serelaxin improved creatinine clearance and renal
blood flow [10–13]. The post hoc analysis on the effect of
serelaxin on biomarkers of end-organ damage was then
followed by a large subgroup analysis, studying the effect
of serelaxin in several subgroups based on clinical char-
acteristics on the endpoints: dyspnea relief by visual analog
scales (VAS) AUC to day 5, the composite of CV death/
rehospitalization for heart failure or renal failure through
day 60, and CV death through day 180. Overall, no evident
differences in the effects of serelaxin vs. placebo were
observed across the subgroups. However, there were some
suggestions that serelaxin may have had a greater treatment
effect in patients with impaired renal function at baseline
[14, 15]. In the present paper, we aimed to investigate
whether serelaxin mitigates the association between renal
impairment and poor clinical outcome in acute heart fail-
ure. In addition, we aimed to study the detailed effects of
serelaxin on other outcomes including total dose of
diuretics, worsening heart failure, hospital stay, days alive
out of the hospital, CV death through day 60 and all-cause
mortality through day 180 in patients with renal impair-
ment at baseline.
Methods
Patient population
For the present analyses, we studied all patients with
available estimated glomerular filtration rate (eGFR) at
baseline enrolled in the RELAX-AHF trial. The methods
and main results of the study have been published in detail
elsewhere [8, 16]. Between October 2009 and February
2012, 1161 acute heart failure patients were randomly
assigned within 16 h of presentation to one of the two
treatment groups in a 1:1 ratio (serelaxin 30 lg/kg per day
or placebo). Eligible patients were adult male or female,
hospitalized for acute heart failure, defined as dyspnea at
rest or with minimal exertion, pulmonary congestion on
chest radiograph and elevated natriuretic peptide levels
[brain natriuretic peptide (BNP) or N-terminal proBNP
(NT-proBNP) levels C350 or C1400 pg/mL, respectively],
requiring at least 40 mg intravenous furosemide or its
equivalent. Further, patients had to have a systolic blood
pressure of [125 mm Hg and mild to moderate renal
function (estimated creatinine clearance of 30–75 ml/min/
1.73 m2). Key exclusion criteria included signs of active
infection, significant pulmonary or valvular disease, acute
heart failure due to significant arrhythmias, acute coronary
syndrome 45 days prior screening or a troponin level[3
times the level diagnostic of myocardial infarction, and
treatment with any other intravenous therapy (except
intravenous nitrate at dose of\0.1 mg/kg in patients with
systolic blood pressure[150 mmHg). The RELAX-AHF
trial was conducted under International Committee on
Harmonization Good Clinical Practices and applicable
country and local regulations, and approved by the Ethics
Committee of each participating site. All patients provided
written informed consent. The RELAX-AHF trial is reg-
istered at Clinicaltrials.gov, number NCT00520806.
Study procedures
Patients were randomized within 16 h of presentation to
one of the two intervention groups receiving either sere-
laxin 30 lg/kg per day or placebo intravenously for up to
48 h continuously. Physical examinations were done, and
patient reported changes in dyspnea severity and general
well-being were measured at baseline (by VAS) and at 6,
12, 24 and 48 h, and then daily to day 5 (by Likert and
VAS). The onset of worsening heart failure (WHF),
worsening of signs or symptoms of heart failure necessi-
tating treatment intensification, was evaluated daily to day
5 and day 14. Patients who died by day 5 without a prior
WHF event were assumed to have had WHF on the day of
death. Patients were followed on days 14, 60 and 180. Non-
serious adverse events (AE) were collected through day 5,
while serious AE (SAE) were reported through day 14.
Renal function
eGFR was calculated by the simplified Modification of
Diet in Renal Disease formula based on creatinine [17–19].
Renal impairment was defined as eGFR \60 ml/min/
1.73 m2. Creatinine was measured in serum using the
Roche CREA plus enzymatic assay (Roche Diagnostics,
Mannheim, Germany).
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Treatment effect of serelaxin in patients with renal
impairment
We studied the treatment effect of serelaxin in all patients
with available eGFR at baseline and patients with an eGFR
under and equal or above 60 ml/min/1.73 m2 at baseline
on the following clinical outcomes: moderate or marked
dyspnea relief by Likert scale at 6, 14 and 24 h, total dose
of intravenous loop diuretic to day 5, total dose of oral loop
diuretic to day 5, worsening heart failure through day 5 and
day 14, length of initial hospital stay (days), length of stay
in intensive care unit (ICU)/coronary care unit (CCU)
(days), days alive out of hospital through day 60, CV death
through day 60 and all-cause mortality through day 180. In
addition, we estimated the number needed to treat (NNT)
to prevent one CV death and to prevent one death from any
cause in patients with renal impairment and the overall
study population.
Statistical analysis
For baseline characteristics, mean (SD), or geometric
mean (95 % CI) if log transformed, was reported for
continuous variables; and frequencies and proportions
(%) for categorical variables (all for patients with non-
missing values of the variable of interest). Baseline
characteristics of patients with and without renal
impairment were compared using t tests (assuming equal
or unequal variances, as appropriate) for continuous
variables and Chi squared or Fisher’s Exact tests for
categorical variables.
To investigate the association between renal impair-
ment and clinical outcomes, and the possible interactions
of serelaxin and renal impairment effects on clinical
outcomes, for continuous outcomes we constructed mul-
tiple linear regression models including the main effects
of renal impairment, treatment group, and their interac-
tion; least square means and mean differences (with 95 %
CIs), and p values for the interaction of treatment with
renal impairment are presented. For binary endpoints, we
generated two-by-two contingency tables to report n (%)
and odds ratios (with 95 % CIs), and used logistic
regression to obtain p values for the interaction of treat-
ment with renal impairment. For time-to-event endpoints,
we present the number of events, Kaplan–Meier estimates
of the event rates, and hazard ratios (with 95 % CIs) and
p values for the interaction of treatment with renal
impairment from Cox proportional hazards models. The
number needed to treat (NNT) was estimated based on
Kaplan–Meier survival probabilities at day 180 by treat-
ment group for the renal impairment subgroup and the
total population [20].
Results
Baseline characteristics of patients enrolled in RELAX-
AHF trial according to eGFR are presented in Table 1. The
subgroup eGFR \60 ml/min/1.73 m2 included 817
patients, the subgroup eGFR C60 ml/min/1.73 m2 included
315 patients. Patients with an eGFR\60 ml/min/1.73 m2
were older, and were more likely to have a history of
hypertension, hyperlipidemia, diabetes mellitus, and
ischemic heart disease.
Association between renal impairment and clinical
outcomes
The association between renal impairment and clinical
outcomes in the overall study population, the serelaxin
group and the placebo group are presented in Table 2. In
the overall study population, renal impairment was sig-
nificantly associated with an increased risk of 180 day CV
(HR 2.00, 95 % CI 1.13–3.54, p for log rank test = 0.016)
and all-cause mortality (HR 1.86, 95 % CI 1.12–3.10, p for
log rank test = 0.015). We found no significant interac-
tions between the association of renal impairment, poor
clinical outcome and study treatment on any outcomes.
However, a trend towards an attenuated association
between renal impairment and mortality was observed in
patients treated with serelaxin. Patients with an
eGFR\60 ml/min/1.73m2 treated with placebo group,
tended to have a higher risk of CV death through day 60
(HR 2.20, 95 % CI 0.76–6.38) compared with patients with
an eGFR\60 ml/min/1.73m2 treated with serelaxin (HR
0.65, 95 % CI 0.26–1.66, p for interaction = 0.093). In the
placebo group, eGFR\60 ml/min/1.73m2 was associated
with CV mortality through day 180 (HR 3.12, 95 % CI
1.33–7.30, while in the serelaxin group, a tendency towards
attenuation of this association was observed (HR 1.19,
95 % CI 0.54–2.64, p for interaction = 0.106). In the
placebo group, eGFR\60 ml/min/1.73m2 was associated
with all-cause mortality through day 180 (HR 2.81, 95 %
CI 1.34–5.89), while in the serelaxin group, a trend towards
attenuation of this association was observed (HR 1.15,
95 % CI 0.56–2.34, p for interaction = 0.088). Figure 1
presents the survival probabilities for patients with and
without renal impairment treated with serelaxin or placebo.
Patients with eGFR\60 ml/min/1.73 m2 treated with pla-
cebo, had worse survival curves compared to both patients
with eGFR\60 ml/min/1.73 m2 treated with serelaxin and
patients with normal renal function regardless of their
study treatment. Figure 2 summarizes the all-cause mor-
tality rate through day 180 in both treatment groups by
baseline eGFR, showing a greater treatment effect of
serelaxin as eGFR is declining.
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Table 1 Baseline characteristics according estimated glomerular filtration rate
Variables eGFR\60 ml/min/1.73 m2 (N = 817)a eGFR C60 ml/min/1.73 m2 (N = 315)a p valueb
Demographics and heart failure characteristics
Age (years) 73.3 (10.6) 68.8 (12.1) \0.001x
Male 505 (61.8) 200 (63.5) 0.601
White/Caucasian 772 (94.5) 301 (95.6) 0.471
Left ventricular ejection fraction (%) 39.2 (14.6) 37.0 (14.3) 0.027*
Ischemic heart disease 443 (54.2) 146 (46.3) 0.018
NYHA class (I/II/III/IV) 30 days before admission 0.130
I 216 (26.7) 100 (31.9)
II 210 (26.0) 84 (26.8)
III 289 (35.7) 90 (28.8)
IV 94 (11.6) 39 (12.5)
Clinical signs
Body mass index (kg/m2) 29.3 (5.7) 29.2 (5.8) 0.918*
Syst. blood pressure (mmHg) 142.4 (16.7) 141.6 (15.8) 0.507*
Diast. blood pressure (mmHg) 78.4 (14.3) 80.7 (13.8) 0.012*
Heart rate, beat per minute 78.9 (14.7) 82.1 (15.2) 0.002*
Serelaxin administration (%) 409 (50.1) 155 (49.2) 0.797
Medical history
Hypertension 720 (88.1) 258 (81.9) 0.006
Hyperlipidemia 454 (55.6) 146 (46.3) 0.005
Diabetes mellitus 414 (50.7) 125 (39.7) 0.001
Cigarette smoking 96 (11.8) 51 (16.2) 0.046
Stroke or other cerebrovascular event 111 (13.6) 42 (13.3) 0.911
Peripheral vascular disease 115 (14.1) 35 (11.1) 0.187
Asthma, bronchitis, or COPD 135 (16.5) 42 (13.3) 0.185
Atrial fibrillation at screening 344 (42.2) 122 (38.7) 0.287
History of Atrial fibrillation or flutter 439 (53.7) 149 (47.3) 0.052
History of CRT or ICD procedures 228 (27.9) 61 (19.4) 0.003
Myocardial infarction 291 (35.6) 101 (32.1) 0.260
Depression 39 (4.8) 19 (6.0) 0.390
Baseline laboratory
Hemoglobin (g/dL) 12.58 (1.89) 13.31 (1.67) \0.001x
Sodium (mmol/L) 140.84 (3.61) 140.80 (3.53) 0.853*
Potassium (mmol/L) 4.33 (0.64) 4.12 (0.59) \0.001*
Uric acid (lmol/L) 490.8 (135.8) 436.9 (128.5) \0.001*
BUN (mmol/L) 10.82 (4.02) 7.09 (2.53) \0.001x
Cystatine C (mg/L)c 1.60 (1.57, 1.63) 1.14 (1.11, 1.17) \0.001*
NT-proBNP (ng/L)c 5567 (5236, 5920) 3883 (3521, 4281) \0.001*
hsTnT (ng/L)c 0.037 (0.035, 0.040) 0.029 (0.026, 0.032) \0.001*
Medication (day 0)
ACE inhibitor 431 (52.8) 189 (60.0) 0.028
ACEi or ARBs 546 (66.8) 227 (72.1) 0.090
Angiotensin-receptor blocker 136 (16.6) 46 (14.6) 0.402
Beta-blocker 565 (69.2) 214 (67.9) 0.692
Aldosterone antagonist 252 (30.8) 105 (33.3) 0.419
Digoxin 167 (20.4) 60 (19.0) 0.600
a Mean (SD), or geometric mean (95 % CI) if log transformed, for continuous variables; n (%) for categorical variables (% based on total
number of patients with non-missing values of the variable of interest)
b P value is based on * t test,  Chi squared test,  Fisher’s Exact test, or the x Satterthwaite method due to unequal variances in comparison
groups. Statistical tests are not adjusted for multiple comparisons
c The following ‘Baseline labs’ variables have been log transformed: hsTnT, NT-proBNP, Cystatine C
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Effects of serelaxin in acute heart failure patients
with renal impairment
We compared the effect of serelaxin on clinical outcomes
in patients with and without renal impairment. The treat-
ment effect of serelaxin in the overall study population is
also summarized in Table 3. A trend towards a higher CV
death toll through day 60 reduction by serelaxin was
observed in patients with renal impairment compared with
patients without renal impairment (HR 0.54 vs. 1.82, p for
interaction = 0.093). A similar trend was observed for
180 day all-cause mortality, showing the beneficial effects
of serelaxin in patients with an eGFR under 60 ml/min/
1.73 m2 compared with patients with an eGFR equal or
above 60 ml/min/1.73 m2 (HR 0.53 vs. 1.30, p for inter-
action = 0.088). Patients treated with serelaxin tended to
require less intravenous (IV) diuretics but more oral
diuretics to day 5, had a shorter stay at the hospital and
ICU/CCU, and had more days alive and out of the hospital
through day 60. These observations were more pronounced
in the eGFR\60 ml/min/1.73 m2 subgroup compared with
the eGFR C60 ml/min/1.73 m2 subgroup although these
interactions were not statistically significant (p for inter-
action IV diuretic = 0.608, p for interaction oral diure-
tic = 0.849, p for interaction initial hospital stay = 0.347,
p for interaction length of stay in ICU/CCU = 0.444, p for
interaction days alive and out of the hospital through day
60 = 0.422; Table 3).
Number needed to treat
The number of patients that needed to be treated with
serelaxin to prevent one CV death through day 180 in
the overall study population was 29. In the
eGFR\60 ml/min/1.73 m2 subgroup, the number nee-
ded to treat (NNT) to prevent one CV death was 19. The
number of patients that needed to be treated with sere-
laxin to prevent one all-cause death during a follow-up
of 180 days in the overall study population was 25. In
the eGFR\60 ml/min/1.73 m2 subgroup, the NNT to
prevent one all-cause death was 16.
Safety of serelaxin
The safety of serelaxin in the overall study population,
and patients with and without renal impairment defined by
eGFR are summarized in Table 4. In general, similar
occurrences of AEs were observed in both treatment
groups in either patients with and without renal impair-
ment. A slight trend towards more AEs was observed in
patients with an eGFR\60 mL/min/1.73 m2 than those
patients with an eGFR C60 mL/min/1.73 m2. Regarding
AEs indicative of renal impairment, more AEs indicating
renal impairment were overall reported for patients with
renal impairment compared with those without renal
impairment. Patients treated with serelaxin experienced
fewer renal AEs regardless of eGFR subgroup. In sub-
group eGFR\60 mL/min/1.73 m2, AEs indicative of
renal impairment through day 5 were reported in 6 % of
patients treated with serelaxin, compared with 10.8 % of
patients treated with placebo. In subgroup eGFR C60 mL/
min/1.73 m2, the proportions were 1.3 % for serelaxin-
treated patients and 2.5 % for patients assigned to pla-
cebo. Overall, the favorable AE profile observed for
serelaxin in RELAX-AHF was maintained in each eGFR
category.
Table 2 Association between renal impairment and clinical outcomes in the all patients, serelaxin group and placebo group
All patients (n = 1132)a Serelaxin (n = 564)a Placebo (n = 568)a Interaction
p valueb
Dyspnea relief by VAS AUC to day 5 -139.39 (-510.72, 231.95) -30.03 (-556.94, 496.88) -253.80 (-774.89, 267.28) 0.554
Dyspnea relief by Likert scale at 6, 12
and 24 h
0.99 (0.74, 1.33) 1.14 (0.74, 1.73) 0.87 (0.58, 1.32) 0.384
Worsening heart failure through day 5 1.16 (0.75, 1.80) 1.48 (0.68, 3.22) 1.04 (0.61, 1.76) 0.460
Worsening heart failure through
day 14
1.28 (0.88, 1.86) 1.70 (0.91, 3.19) 1.07 (0.67, 1.71) 0.246
CV death/re-hospitalization for HF/RF
through day 60 (days)
1.39 (0.94, 2.06) 1.14 (0.67, 1.95) 1.72 (0.96, 3.08) 0.311
CV death through day 60 (days) 1.21 (0.61, 2.38) 0.65 (0.26, 1.66) 2.20 (0.76, 6.38) 0.093
CV death through day 180 2.00 (1.13, 3.54) 1.19 (0.54, 2.64) 3.12 (1.33, 7.30) 0.106
All-cause mortality day 180 1.86 (1.12, 3.10) 1.15 (0.56, 2.34) 2.81 (1.34, 5.89) 0.088
a Effect of eGFR\60 mL/min/1.73m2 is estimated: LS mean difference (95 % CI) for continuous endpoints, odds ratio (95 % CI) from 2 9 2
contingency table for binary endpoints, and hazard ratio (95 % CI) from Cox proportional hazards model for time-to-event endpoints
b Interaction p values are based on tests of treatment-by-eGFR interaction. Interaction p values are obtained using Cox regression for time-to-
event endpoints, logistic regression for binary endpoints, and multiple linear regression for continuous endpoints
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Discussion
In the current post hoc analysis of the RELAX-AHF trial,
we demonstrate that baseline renal dysfunction
(eGFR\60 mL/min/1.73 m2) was associated with worse
clinical outcomes in acute heart failure patients treated
with placebo. Serelaxin appears to attenuate this effect,
though this trend was not statistically significant. More-
over, in acute heart failure patients with renal dysfunction,
treatment with serelaxin resulted in larger reductions of
60 day CV death and 180 day all-cause mortality com-
pared with patients without renal dysfunction, and a lower
NNT compared to the overall study population. Our find-
ings suggest that treatment with serelaxin may have a
greater treatment effect in patients with renal dysfunction
and that the observed reduction of (cardiovascular) mor-
tality by serelaxin seems to be driven by more pronounced
effects in patients with more severe renal dysfunction.
Renal dysfunction is common in patients with acute
heart failure and is associated with increased mortality and
rehospitalization [1, 2]. In fact, the prognostic value of
renal impairment in patients with heart failure remained
consistent even across a large number of studies, as was
recently demonstrated by Damman and colleagues in a
Fig. 1 Kaplan–Meier curves
for cardiovascular (CV) death
through day 180 (a upper panel)
and all-cause death through day
180 (b lower panel) according
to eGFR. eGFR estimated
glomerular filtration rate
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meta-analysis including 1,076,104 heart failure patients
[21].
Recent studies demonstrated that both relaxin and its
receptor are expressed in the heart and kidney [22–25],
suggesting that relaxin may also have direct renal effects.
Indeed, previous pre-clinical studies in rats have demon-
strated that relaxin causes renal vasodilatation, resulting in
increased renal plasma flow and glomerular filtration rate,
protecting the kidney against renal ischemia–reperfusion
injury, and attenuating renal fibrosis [26–30]. In both
healthy humans and patients with chronic stable heart
failure, administration of serelaxin resulted in an increased
renal blood flow [11, 12]. Furthermore, angiotensin II
induced renal vasoconstriction was reversed by relaxin,
underscoring the renal protective effects of relaxin [27].
Post hoc analysis of the RELAX-AHF demonstrated that
treatment with serelaxin was associated with a lower
increase in markers of end-organ damage, including the
renal markers creatinine and cystatin C; although serelaxin
was administered for 48 h, creatinine levels remained
lower through day 5, while cystatine C levels even
remained lower through day 14 compared to the placebo
group [9]. These observations suggest that serelaxin might
possess renal protective properties that may even result in
long-term beneficial effects after its administration in acute
heart failure patients.
In our study, we found no significant interactions
between the association of renal impairment and poor
clinical outcome and study treatment. However, a trend
was observed suggesting that patients with renal dysfunc-
tion treated with placebo had a higher risk for CV mortality
and all-cause mortality compared to patients with renal
dysfunction treated with serelaxin. Interestingly, the
survival curves of patients with renal dysfunction treated
with serelaxin were almost comparable with the survival
curves of patients with normal renal function, irrespective
of their study treatment. When we studied the treatment
effect of serelaxin more in depth on other clinical outcomes
[31], we found overall higher treatment estimates of sere-
laxin in the eGFR\60 ml/min/1.73 m2 subgroup, com-
pared with the eGFR C60 ml/min/1.73 m2 subgroup.
Although these interactions were not statistically signifi-
cant, our results suggest that serelaxin may have a greater
treatment effect in patients with renal impairment; patients
with renal impairment treated with serelaxin had greater
dyspnea relief, shorter stay in the hospital, and lower use of
IV diuretics. It should be noted that the lower diuretic
requirement might also explain the favorable changes in
levels of the renal markers. In terms of CV through day 60
and all-cause mortality through day 180, treatment with
serelaxin resulted in a greater treatment benefit in patients
with an eGFR\60 ml/min/1.73 m2 compared with
patients with an eGFR C60 ml/min/1.73 m2. In addition,
we found a lower NNT in both the eGFR\60 ml/min/
1.73 m2 subgroups for CV mortality, as well as all-cause
mortality, compared with the overall study population.
Because the NNT is the inverse of the absolute risk
reduction, the NNT will vary according to the event rates
of both subgroups, since it is expected that a higher clinical
risk is related with a higher absolute risk reduction. How-
ever, we demonstrated that the relative risk reduction by
treatment with serelaxin was also not homogeneous among
the RELAX-AHF study population. The kidney itself is
evidently a target organ for relaxin activity and this may
explain why patients with renal impairment may benefit
more from the renoprotective effects of serelaxin admin-
istration. In addition, as these patients are at higher clinical
risk, treatment may have had greater impact in these
patients compared to ‘low risk’ patients. Our results illus-
trate that a patient’s baseline risk may interact with treat-
ment in a clinically relevant manner and that the overall
treatment effect may not reflect the treatment effect of the
individual patients [32].
In addition to the well-known expected limitations of
such post hoc and retrospective analyses, the present study
has several limitations. Subgroup analyses are necessary to
evaluate potential heterogeneity in treatment effect, but our
results demonstrate that these analyses are associated with
statistical concerns [33, 34]. The subgroup eGFR C60 ml/
min/1.73 m2 had a smaller sample size and while the
estimates of treatment effect of serelaxin were slightly
higher in the eGFR\60 ml/min/1.73 m2 subgroup, the
present study lacks the power to detect treatment interac-
tions between subgroups. In addition, the subgroup
eGFR C60 ml/min/1.73 m2 was relatively small and had
lower number of events. The mortality rates for this
Fig. 2 Percentage of death through day 180 in subgroups according
to estimated glomerular filtration (eGFR) rate in acute heart failure
patients treated with placebo (blue) or serelaxin (red). (1) *p\ 0.05;
(2) eGFR interval 41.5–51.2 stands for C41.5 and\51.2; 51.2–61.2
stands for C51.2 and\61.2
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subgroup were 14/315 = 4.4 % for CV mortality and
18/315 = 5.7 % for all-cause mortality. The small number
of patients and events may have limited our analysis and
interpretation of the results of this subgroup. One could
also suggest that it may have been difficult for any treat-
ment to have an impact in these ‘low risk’ patients. Further,
not every patient had eGFR at baseline. Since the RELAX-
AHF trial only enrolled patients with renal function
30–75 ml/min/1.73 m2, we could not assess the effects of
serelaxin of patients with a renal function out of these
ranges. As the subgroups were not pre-specified, our results
should be interpreted with caution. Cystatin C was mea-
sured in the RELAX-AHF trial and is proposed as a better
and more reliable marker of renal function as cystatin C is
unaffected by increases in age, diet, and muscle mass [35–
40]. Unfortunately, cystatin C was not measured in all
patients who were enrolled in the RELAX-AHF trial. The
number of patients with missing values of cystatin C
formed a limitation for the analysis of eGFR estimated by
cystatin C. Therefore, we did not include analyses on eGFR
estimated by cystatin C in the current paper. It should also
be noted that the primary endpoint of the RELAX-AHF
trial was dyspnea relief. Other outcomes regarding total
dose of diuretic, worsening heart failure, hospital stay, CV
death through day 60 and all-cause mortality through day
180 were not among the primary endpoints of the RELAX-
AHF trial. Thus, the RELAX-AHF study was not primarily
designed to address these endpoints. Currently, the repli-
cate phase III study is ongoing, studying the effect of
serelaxin on CV death and other clinical outcomes
Table 4 Overview of all-treatment emergent AEs regardless of study drug relationship by eGFR through day 5 and day 14
Adverse event (AE) subset; n (%) eGFR category
All patientsa eGFR\60 mL/min/1.73 m2 eGFR C60 mL/min/1.73 m2
Serelaxin
(N = 568)
Placebo
(N = 570)
Serelaxin
(N = 403)
Placebo
(N = 406)
Serelaxin
(N = 155)
Placebo
(N = 157)
AEs through day 5
Any AEs 280 (49.3) 305 (53.5) 209 (51.9) 231 (56.9) 66 (42.6) 70 (44.6)
Any AEs leading to drug
discontinuation
26 (4.6) 22 (3.9) 16 (4.0) 16 (3.9) 10 (6.5) 5 (3.2)
SAEs 36 (6.3) 38 (6.7) 27 (6.7) 29 (7.1) 8 (5.2) 7 (4.5)
SAEs with an outcome of death 6 (1.1) 9 (1.6) 4 (1.0) 6 (1.5) 2 (1.3) 2 (1.3)
AEs through day 14
All-treatment emergent AEs 305 (53.7) 320 (56.1) 229 (56.8) 243 (59.9) 70 (45.2) 73 (46.5)
SAEs 86 (15.1) 78 (13.7) 68 (16.9) 58 (14.3) 16 (10.3) 18 (11.5)
SAEs with an outcome of death 10 (1.8) 15 (2.6) 7 (1.7) 10 (2.5) 3 (1.9) 4 (2.5)
AEs indicative of renal impairment through day 5
Subjects with any AE 26 (4.6) 49 (8.6) 24 (6.0) 44 (10.8) 2 (1.3) 4 (2.5)
Azotaemia 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.2) – –
Blood creatinine increased 14 (2.5) 22 (3.9) 12 (3.0) 19 (4.7) 2 (1.3) 3 (1.9)
Oliguria 0 1 (0.2) – – 0 1 (0.6)
Proteinuria 0 2 (0.4) 0 2 (0.5) – –
Renal failure 9 (1.6) 23 (4.0) 9 (2.2) 21 (5.2) 0 1 (0.6)
Renal failure acute 1 (0.2) 0 1 (0.2) 0 – –
Renal impairment 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.2) – –
AEs indicative of renal impairment through day 14
Subjects with any AE 32 (5.6) 51 (8.9) 30 (7.4) 46 (11.3) 2 (1.3) 4 (2.5)
Azotaemia 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.2) – –
Blood creatinine increased 14 (2.5) 23 (4.0) 12 (3.0) 20 (4.9) 2 (1.3) 3 (1.9)
Oliguria 0 1 (0.2) – – 0 1 (0.6)
Proteinuria 0 2 (0.4) 0 2 (0.5) – –
Renal failure 14 (2.5) 25 (4.4) 14 (3.5) 23 (5.7) 0 1 (0.6)
Renal failure acute 2 (0.4) 0 2 (0.5) 0 – –
Renal impairment 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.2) – –
a eGFR was 30–75 mL/min/1.73 m2 according to the inclusion criteria
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(RELAX-AHF-2 trial, NCT01870778). Whether treatment
with serelaxin results in a greater treatment benefit in
patients with an eGFR\60 mL/min/1.73 m2 should be
further investigated.
In summary, treatment with serelaxin was safe and
effective and trends towards an attenuation of the well-
known association between renal dysfunction and clinical
outcomes were observed in patients treated with serelaxin.
Our results suggest that serelaxin has a greater treatment
benefit in terms of reducing CV and all-cause mortality in
patients with an eGFR\60 mL/min/1.73 m2. However, as
these were not the primary endpoints of the RELAX-AHF
trial, this finding should be interpreted with caution and
ongoing and future studies with larger sample sizes are
needed to confirm these findings. Our findings may empha-
size the safety profile of serelaxin, as these patients are
considered to be more vulnerable and at higher clinical risk.
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